IndexIQ Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

IndexIQ Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$406K	Sell	8,196 -1,922	-19%	-$92.2K	0.01%	595
2021 Q4	$515K	Sell	10,118 -653	-6%	-$33.8K	0.02%	543
2021 Q3	$601K	Buy	10,771 +1,079	+11%	+$53.1K	0.02%	438
2021 Q2	$415K	Sell	9,692 -83	-0.8%	-$3.42K	0.01%	650
2021 Q1	$408K	Buy	+9,775	New	+$454K	0.01%	544
2020 Q1	–	Sell	-16,065	Closed	-$965K	–	1147
2019 Q4	$965K	Sell	16,065 -5,098	-24%	-$304K	0.03%	277
2019 Q3	$1.2M	Sell	21,163 -3,967	-16%	-$223K	0.04%	276
2019 Q2	$1.4M	Sell	25,130 -6,452	-20%	-$337K	0.04%	255
2019 Q1	$1.59M	Buy	+31,582	New	+$1.41M	0.05%	243

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SGCIA

Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

IndexIQ Advisors's EGRX Position: Q1 2022 in Review

IndexIQ Advisors reduced its Eagle Pharmaceuticals, Inc. (EGRX) stake by 19% in Q1 2022, selling an estimated $92.2K and leaving 8,196 shares worth $406K. The position accounts for 0.01% of the portfolio, ranked #595.

IndexIQ Advisors first reported a position in EGRX in Q1 2019 and has held it in 9 quarters since. The position peaked at $1.59M in Q1 2019. 160 funds tracked by Wall St. Rank hold EGRX as of Q1 2022.

IndexIQ Advisors held 8,196 shares of Eagle Pharmaceuticals, Inc. worth $406K as of Q1 2022.
IndexIQ Advisors sold 1,922 Eagle Pharmaceuticals, Inc. shares in Q1 2022, an estimated $92.2K.
Eagle Pharmaceuticals, Inc. made up 0.01% of IndexIQ Advisors's portfolio in Q1 2022, its #595 holding.
IndexIQ Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2019 and has held it in 9 quarters since.
IndexIQ Advisors's Eagle Pharmaceuticals, Inc. position peaked at $1.59M in Q1 2019.
160 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.